(Total Views: 565)
Posted On: 04/06/2017 4:16:49 PM
Post# of 15624
Re: NotRichYet2 #5910
Wow, NTRP up to $29.00 from $5.76 low in December.
Mid-February is where they shot up and this article may explain why:
Neurotrope BioScience (NASDAQ:NTRP) is a three-year-old biotech company on the verge of releasing results from a Phase II trial testing its new Alzheimer's drug. Its drug has a plausible mechanism of action, solid preclinical research, encouraging Phase I data, and a well-respected team of scientists behind it. If the trial results are favorable, NTRP is likely to rise tenfold or more.
Mid-February is where they shot up and this article may explain why:
Neurotrope BioScience (NASDAQ:NTRP) is a three-year-old biotech company on the verge of releasing results from a Phase II trial testing its new Alzheimer's drug. Its drug has a plausible mechanism of action, solid preclinical research, encouraging Phase I data, and a well-respected team of scientists behind it. If the trial results are favorable, NTRP is likely to rise tenfold or more.
(0)
(0)
